Syncona — 2020 Investments
1 investments dated 2020 · listed companies and verified rows first · show all
Neogene Therapeuticsneogene.comSep 2020Acquired
Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.
BiotechNew York, US
Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)
BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)
Board seatElisa Petris· per SEC Form D
Co-investorsEcoR1 CapitalJeito CapitalVida VenturesTPG
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.